Sorrento Schedules Three Preclinical Poster Presentations On Cynviloq

(RTTNews) - Sorrento Therapeutics, Inc. (SRNE), a late-stage clinical oncology company, said it has scheduled three preclinical abstracts for poster presentations at the 106th Annual Meeting of the American Association for Cancer Research or AACR, to be held April 18-22, 2015 in Philadelphia, Pennsylvania.

The company will present data including studies on the significant reduction in tumor burden and enhanced survival following Cynviloq intraperitoneal therapy, compared to albumin-bound paclitaxel intravenous therapy in a metastatic model of ovarian cancer, successful development of anti-cancer antibody drug conjugates using novel C- and K-lock linker technology, and significant efficacy of its c-Met/EGFR Bispecific Targeting ADC in a non-small cell lung cancer model.